Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)

被引：1

作者：

Xu, J. ^{[1
]}

Shen, L. ^{[2
]}

Bai, C. ^{[3
]}

Li, J. ^{[2
]}

Zhou, Z. ^{[4
]}

Yu, X. ^{[5
]}

Li, Z. ^{[6
]}

Li, E. ^{[7
]}

Yuan, X. ^{[8
]}

Chi, Y. ^{[9
,10
]}

Yin, Y. ^{[11
]}

Lou, W. ^{[12
]}

Xu, N. ^{[13
]}

Bai, Y. ^{[14
]}

Zhang, T. ^{[15
]}

Xiu, D. ^{[16
]}

Wang, X. ^{[17
]}

Li, J. ^{[2
]}

Fan, S.

Su, W. ^{[18
]}

机构：

[1] Gen Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China

[2] Peking Univ Canc Hosp & Inst, Dept GI Oncol, Beijing, Peoples R China

[3] Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China

[4] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Gastr Surg,Canc Ctr, Guangzhou, Guangdong, Peoples R China

[5] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai, Peoples R China

[6] Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Sichuan, Peoples R China

[7] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Shaanxi, Peoples R China

[8] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Hubei, Peoples R China

[9] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China

[10] Peking Union Med Coll, Beijing, Peoples R China

[11] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China

[12] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China

[13] Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[14] Harbin Med Univ Canc Hosp, Dept Gastrointestinal Oncol, Harbin, Peoples R China

[15] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan, Hubei, Peoples R China

[16] Peking Univ, Hosp 3, Dept Gen Surg, Beijing, Peoples R China

[17] Shandong Univ, Qilu Hosp, Dept Med Oncol, Jinan, Peoples R China

[18] Hutchison MediPharma Ltd, Clin Dept & Regulatory Affairs, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1369

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1156O

引用

页码：S770 / S770

页数：1

共 50 条

[21] DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED PHASE III TRIAL OF AFLIBERCEPT (A) PLUS GEMCITABINE (G) VERSUS PLACEBO (P) PLUS GEMCITABINE (G) IN PATIENTS WITH METASTATIC PANCREATIC CANCER: FINAL RESULTS
Riess, H.
Manges, R.
Karasek, P.
Humblet, Y.
Barono, C.
Santoro, A.
Wojcik-Tomaszewska, J.
Assadourian, S.
Hatteville, L.
Vincent, G.
Philip, P.
Rougier, P.
ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
[22] SPINET: A Randomized, Double-blind, Placebo-controlled Phase III Study of Lanreotide Autogel/Depot (LAN) in Patients with Advanced Lung Neuroendocrine Tumors
Reidy-Lagunes, Diane
Kulke, Matthew
Wolin, Edward
Singh, Simron
Ferone, Diego
Mirakhur, Beloo
Hoffmanns, Philipp
Houchard, Aude
Caplin, Martyn
Baudin, Eric
PANCREAS, 2017, 46 (03) : 451 - 451
[23] Subgroup analysis by Ki-67 and primary tumour origins of the randomized, placebo-controlled phase III study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumours (SANET-ep)
Zhou, Z.
Xu, J.
Shen, L.
Li, J.
Bai, C.
Chi, Y.
Li, Z.
Xu, N.
Jia, R.
Li, E.
Liu, T.
Bai, Y.
Yuan, Y.
Li, X.
Wang, X.
Chen, J.
Wang, W.
Li, J.
He, J.
Su, W.
ANNALS OF ONCOLOGY, 2020, 31 : S775 - S775
[24] Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Chesney, Jason A.
Ribas, Antoni
Long, Georgina, V
Kirkwood, John M.
Dummer, Reinhard
Puzanov, Igor
Hoeller, Christoph
Gajewski, Thomas F.
Gutzmer, Ralf
Rutkowski, Piotr
Demidov, Lev
Arenberger, Petr
Shin, Sang Joon
Ferrucci, Pier Francesco
Haydon, Andrew
Hyngstrom, John
van Thienen, Johannes, V
Haferkamp, Sebastian
Guilera, Josep Malvehy
Rapoport, Bernardo Leon
VanderWalde, Ari
Diede, Scott J.
Anderson, James R.
Treichel, Sheryl
Chan, Edward L.
Bhatta, Sumita
Gansert, Jennifer
Hodi, Frank Stephen
Gogas, Helen
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 528 - +
[25] Re: Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial
Culp, Stephen H.
Wood, Christopher G.
EUROPEAN UROLOGY, 2009, 55 (06) : 1484 - 1485
[26] Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Blay, Jean-Yves
Serrano, Cesar
Heinrich, Michael C.
Zalcberg, John
Bauer, Sebastian
Gelderblom, Hans
Schoffski, Patrick
Jones, Robin L.
Attia, Steven
D'Amato, Gina
Chi, Ping
Reichardt, Peter
Meade, Julie
Shi, Kelvin
Ruiz-Soto, Rodrigo
George, Suzanne
von Mehren, Margaret
LANCET ONCOLOGY, 2020, 21 (07): : 923 - 934
[27] An International, Randomized, Double-blind, Placebo-controlled, Phase III Trial of Pregabalin Monotherapy in Treatment of Patients with Fibromyalgia
Pauer, Lynne
Winkelmann, Andreas
Arsenault, Pierre
Jespersen, Anders
Whelan, Laurence
Atkinson, Gary
Leon, Teresa
Zeiher, Bernhardt
JOURNAL OF RHEUMATOLOGY, 2011, 38 (12) : 2643 - 2652
[28] Randomized, Double-blind, Placebo Controlled Phase III Trial of Oxymetholone for the Treatment of HIV Wasting and Lipodystrophy
Priyo Sasongko
Retrovirology, 2
[29] Randomized, double-blind, placebo controlled phase III trial of oxymetholone for the treatment of HIV wasting and lipodystrophy
Sasongko, Priyo
RETROVIROLOGY, 2005, 2 (Suppl 1)
[30] Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting
Hengge, UR
Stocks, K
Wiehler, H
Faulkner, S
Esser, S
Lorenz, C
Jentzen, W
Hengge, D
Goos, M
Dudley, RE
Gham, GR
AIDS, 2003, 17 (05) : 699 - 710

← 1 2 3 4 5 →